Video Experimental Relacionado
Updated: Sep 9, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.8K
Funciones alternativas de los anticoagulantes fisiológicos
Teagan Prouse1, Alan E Mast2, Vera Ignjatovic3
1Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States.
Journal of thrombosis and haemostasis : JTH
|September 4, 2025
Resumen
Los anticoagulantes fisiológicos como la antitrombina (AT) y la proteína C (PC) tienen diversas funciones más allá de la coagulación de la sangre. Investigaciones recientes revelan su potencial en el tratamiento de enfermedades como el cáncer y el derrame cerebral.
Área de la Ciencia:
- Fisiología
- Hematología
- Farmacología
Sus antecedentes:
- Las proteínas anticoagulantes, incluidas la antitrombina (AT), la proteína C (PC), la proteína S (PS) y el inhibidor de la vía del factor tisular (TFPI), son reguladores cruciales de la hemostasis.
- Estas proteínas poseen actividades anticoagulantes y ejercen funciones fisiológicas alternativas que afectan a diversas enfermedades más allá de la trombosis y el sangrado.
- Comprender estas funciones multifacéticas es clave para desarrollar nuevas estrategias terapéuticas.
Objetivo del estudio:
- Revisar la literatura reciente (2018-2025) sobre las funciones fisiológicas alternativas de AT, PC, PS y TFPI en la enfermedad clínica.
- Explorar las aplicaciones terapéuticas de estos anticoagulantes en diversos campos médicos.
- Para resaltar las vías terapéuticas emergentes basadas en las funciones no hemostáticas de estas proteínas.
Principales métodos:
- Búsqueda completa de literatura de PubMed para artículos publicados entre 2018 y principios de 2025.
- Selección enfocada de estudios que investigan funciones alternativas de AT, PC, PS y TFPI en varias categorías de enfermedades clínicas.
- Categoría de aplicaciones terapéuticas seleccionadas que incluyen cáncer, enfermedades cardiovasculares, salud del embarazo, inflamación, infección, accidente cerebrovascular y más.
Principales resultados:
- Se han identificado implicaciones significativas de las funciones AT, PC, PS y TFPI más allá de la anticoagulación.
- Aplicaciones terapéuticas emergentes documentadas en oncología, medicina cardiovascular, neurología y enfermedades infecciosas.
- Se destacaron nuevas interacciones con las células endoteliales y las plaquetas, y roles en la protección de la barrera hematoencefálica.
Conclusiones:
- Las diversas funciones fisiológicas de AT, PC, PS y TFPI ofrecen un potencial terapéutico prometedor para una amplia gama de enfermedades humanas.
- Una mayor investigación sobre estas funciones alternativas puede desbloquear nuevas estrategias de tratamiento.
- Estos hallazgos subrayan la importancia de considerar los anticoagulantes para las afecciones no trombóticas.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
888
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
888
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
642
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
642
01:16Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.1K